The next wave dual and triple agonists (GLP-1 + GIP + glucagon: tirzepatide, retatrutide, survodutide) are showing superior fat loss, better hepatic outcomes, and potentially preserved lean mass
This combination is designed to support weight loss efforts, boost metabolism, and promote liver health [2]
These changes do not happen identically in every woman, but they are common enough to shape how medications are experienced
& Davamani, F
Intra-colonic propionate increases plasma gut hormone levels via an FFA2-dependent mechanism in mice To determine whether the reduced PYY and GLP-1 secretory responses to propionate observed in primary colonic cultures from FFA2 / mice in vitro translated into impaired gut hormone secretion from these mice in vivo , portal vein plasma PYY and GLP-1 responses to a single intra-colonic injection of propionic acid (180 mmol l 1 ) or saline control were investigated in FFA2 / mice compared with their WT littermates
The dosage, duration, measured outcomes, and key findings for each pharmacological category are summarized in Table 3